Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0486 + R-mini-CHOP vs R-mini-CHOP in Newly Diagnosed Large B-cell Lymphoma
NCT07215585Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2025
- Primary completion
- Jun 2030
- Modality
- Bispecific Antibodies, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 12
01
Overview
A Phase 3 trial of surovatamig in diffuse large B-cell lymphoma (DLBCL), sponsored by AstraZeneca. Started Nov 2025; status: recruiting.
02
Drugs
surovatamig
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07215585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215585.